Overview

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors

Status:
Recruiting

Trial end date:
2027-12-01

Target enrollment:

Participant gender:

Summary

A FIH study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VVD-130850, as single agent and in combination with checkpoint inhibition, in participants with advanced solid and hematologic tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Vividion Therapeutics, Inc.

Treatments:

Pembrolizumab